Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 6Lung Neoplasms 6Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1

Interventions

Induction Chemotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ESCC × Immunotherapy × Clear all
NCT07015489 2025-06-11

Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Completed
44 enrolled

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡